In the ever-evolving global landscape of cell therapy development, selecting quality raw materials is crucial for achieving clinical and commercial milestones. In this Innovator Insight article, Kyle Hondorp asks industry experts, Kasey Kime and Lili Belcastro, to share insights into the key factors influencing raw material selection throughout different phases of development. Kyle Hondorp also discusses the Gibco™ Cell Therapy Systems (CTS™) portfolio of fit-for-purpose media and reagents, cell therapy instrumentation, and viral vector systems, which are GMP manufactured, safety tested, and backed by regulatory documentation to support cell and gene therapy developers along their path to commercialization.

提供商	赛默飞世尔科技（中国）有限公司	下载次数	0次
资料大小	3.7MB	资料类型	PDF 文件 免费下载该资料
资料图片	--	浏览次数	38次